RP-3 by Replimune for Lung Cancer: Likelihood of Approval

LAMA2-CMD is an early onset congenital muscular dystrophy caused by the absence of the LAMA2 protein. Image credit: Shutterstock/ Dan76. Modalis Therapeutics has been awarded

Saris­sa Cap­i­tal Man­age­ment’s three nom­i­nees to the Alk­er­mes board failed to gain enough votes at a share­hold­er meet­ing, and all sev­en of the com­pa­ny’s board